Search
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedTocofersolan is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of [DB11251]. … Moreover, the agent is capable of demonstrating antioxidant effects that make it a popular component to include in cosmetics and pharmaceuticals as well.
Mixtures: Eye Health Areds 2 FormulaCategories: Vitamin E, Cytochrome P-450 SubstratesFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalAs the half-life of endogenous Factor XIII is long (5-11 days), prophylactic therapy with the replacement of FXIII can be given every 4-6 to maintain hemostasis[A32363]. … When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.
International brands: Fibrogammin PFlecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawnFlecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. … [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
Categories: Antiarrhythmics, Class I, MATE 1 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideZoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigationalZoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. … [A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.
Salts: Zoledronate D,L-Lysine MonohydrateCategories: Heterocyclic Compounds, 1-RingFluorouracil
go.drugbank.com/drugs/DB00544ApprovedInvestigationalA pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Synonyms: 5 FU, 5-FUMixtures: Actikerall 5 mg/g + 100 mg/g Lösung zur Anwendung auf der Haut, VERRUTOL %0,5 + %10 DERİ ÇÖZELTİSİ (15 G)Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: อินเดอร์จิน 1 มก., นิวโรจีน 1 มิลลิกรัมMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAnethole trithione
go.drugbank.com/drugs/DB13853ApprovedAnethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to … for many of these aforementioned functions at this time and is only used in limited regions around the world.
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigationalZolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
Synonyms: Optimised human arginase I, Co-ArgI-PEG modified human arginase I